Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced / Metastatic Solid Tumors

This study is an open-label Phase 1 / Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced / metastatic solid tumors.
Miscellaneous, Phase I
Phase I
Adults
Mol. targeted/Immunotherapy/Biologics
INCB001158, MK-3475, Pembrolizumab (MK-3475)
Gibson, Mike
National
Vanderbilt University
08-17-2018
Treatment
VICCPHI1841
NCT02903914

Eligibility

Not Available
Not Available
NO
Inclusion Criteria:

Must be age 18 or older

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: